PAVmed Inc. Enters Sales Agreement for $9.4M At-the‑Market Offering

What Happened
PAVmed Inc. (PAVM) announced on September 9, 2026 that it entered into a Sales Agreement with A.G.P./Alliance Global Partners to conduct an at‑the‑market (ATM) offering of its common stock. The company may sell up to $9,400,000 of shares under the prospectus supplement filed the same day, using its effective Form S‑3 shelf registration (File No. 333‑283994, declared effective April 15, 2025). Proceeds are intended for working capital and general corporate purposes.

Key Details

• Agent: A.G.P./Alliance Global Partners; offering conducted as an "at‑the‑market" sale under Rule 415.
• Maximum size as of filing: $9,400,000 of Shares per the prospectus supplement.
• Agent fees and expenses: 3.0% commission on gross sales; legal counsel fees reimbursed up to $65,000 (initial), $7,500 per quarter (representation dates), and $12,500 per program refresh.
• Agreement terms: customary reps, covenants, indemnities; terminable by either party with ten business days’ written notice (Agent may terminate immediately in certain circumstances).

Why It Matters
This 8‑K signals that PAVmed has an on‑going mechanism to raise equity capital quickly as market conditions allow, up to the disclosed $9.4M. For investors, an ATM can dilute existing shares if used, but it also provides the company flexibility to fund operations without negotiating larger, single financing rounds. The announced fees and reimbursement caps define the cost of using the program.